Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

Shelley, et al., Yesterday I filled out this form

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 155485
(Total Views: 690)
Posted On: 08/23/2020 6:41:35 PM
Posted By: Cassandra X
Re: Shelly2626 #51763
Shelley, et al., Yesterday I filled out this form at the NIH "Portal" where any and everyone is encouraged to let NIAID know about anything they think will help fight Covid-19.

https://grants.nih.gov/grants/rfi/rfi.cfm?ID=107

I think having a bunch of people fill out this form and advocate for Cytodyn and Leronlimab wouldn't be a bad idea. Let's call their bluff. I filled out the form as an "Advocate". Here is what I said in the comment section -

I see that NIH is enrolling candidates for therapeutics to fight Covid-19. Is NIH unaware that a highly effective therapeutic for Covid-19 already exists and is in trials with the FDA?

The therapeutic in a humanized monoclonal antibody made by Cytodyn Inc. in Vancouver, Washington and is called Leronlimab. Cytodyn has filed for a BLA for Leronlimab to treat HIV and is in Phase 3 trials for treating Covid-19 for severe to critical patients and has just finished Phase 2 trials for mild to moderate cases of Covid-19 and has applied for Emergency Use Authorization.

The safety profile of Leronlimab has proven to be excellent in all uses. Some trial participants in the HIV trials have been using it for 6 years. There have been no serious safety concerns ever.

Leronlimab should be granted EUA status and should be made the Standard of Care for Covid-19 immediately, replacing the current SOC, Remdesivir.

I have searched NIH's website and I find no evidence that you are aware of Cytodyn and Leronlimab. Is this true? If so, please research Cytodyn and Leronlimab and add them to your database. Also please call Cytodyn at 360-980-8524.

Thank you.

You could also add now that Plasma is crap by comparison!


(1)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us